Rapport Therapeutics (RAPP) Earnings Date, Estimates & Call Transcripts $23.05 -4.98 (-17.76%) As of 10:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Rapport Therapeutics Earnings Summary Rapport Therapeutics issued Q2 2025 earnings on August 7, 2025, reporting an EPS of -$0.75, which beat analysts' consensus estimates of -$0.87 by $0.12. With a trailing EPS of -$2.50, Rapport Therapeutics' earnings are expected to grow next year, from ($3.65) to ($3.37) per share. Upcoming Q3 Earnings DateNov. 6Before Market OpensEstimatedConsensus EPS (Aug. 7) -$0.87 Actual EPS (Aug. 7) -$0.75 Beat By $0.12 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)RAPP Upcoming EarningsRapport Therapeutics' next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules. Powered by Get Rapport Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapport Therapeutics and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataRAPP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Rapport Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ2 20251-$0.71-$0.71-$0.71Q3 20251-$0.79-$0.79-$0.79Q4 20251-$0.73-$0.73-$0.73 2025 3 -$2.23 -$2.23 -$2.23 Q1 20261-$0.79-$0.79-$0.79Q2 20261-$0.79-$0.79-$0.79Q3 20261-$0.86-$0.86-$0.86Q4 20261-$0.85-$0.85-$0.85 Rapport Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/6/2025(Estimated)--------8/7/2025Q2 2025-$0.87-$0.75+$0.12-$0.75--5/8/2025Q1 2025-$0.77-$0.68+$0.09-$0.68--11/7/2024--$0.57-$0.50+$0.07-$0.50--8/8/2024--$0.68-$1.70 -$1.02-$1.70-- Rapport Therapeutics Earnings - Frequently Asked Questions When is Rapport Therapeutics' earnings date? Rapport Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based off last year's report dates. Learn more on RAPP's earnings history. Did Rapport Therapeutics beat their earnings estimates last quarter? In the previous quarter, Rapport Therapeutics (NASDAQ:RAPP) reported ($0.75) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.87) by $0.12. Learn more on analysts' earnings estimate vs. RAPP's actual earnings. How much profit does Rapport Therapeutics generate each year? Rapport Therapeutics (NASDAQ:RAPP) has a recorded net income of -$78.31 million. RAPP has generated -$2.50 earnings per share over the last four quarters. What is Rapport Therapeutics' EPS forecast for next year? Rapport Therapeutics' earnings are expected to grow from ($3.65) per share to ($3.37) per share in the next year. More Earnings Resources from MarketBeat Related Companies Immunovant Earnings Kiniksa Pharmaceuticals International Earnings Tarsus Pharmaceuticals Earnings Organon & Co. Earnings Alvotech Earnings Centessa Pharmaceuticals Earnings Denali Therapeutics Earnings ImmunityBio Earnings Agios Pharmaceuticals Earnings IDEAYA Biosciences Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why DocuSign Could Be a SaaS Value Play After Q2 EarningsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples Play This page (NASDAQ:RAPP) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersWall Street Legend Issues Urgent AI Stock WarningChaikin's stepping forward with a new warning – focused on the red-hot A.I. frenzy taking the U.S. stock marke...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RAPP Stock Alerts